The role of genetics in developing chronic pain is still being researched and better understood. However, there is a tentative belief that a genetic risk factor may exist. Also being examined is the genetics behind the actual condition - the biology of chronic pain. In this case, certain genes and hormones seem to be behind pain.
The FDA has approved Hysingla ER, a once-daily, single-entity hydrocodone product. What makes Hysingla ER unique is that it is the first and so far the only hydrocodone product to be recognized by the FDA as having abuse-deterrent properties that are expected to reduce, but not totally prevent, abuse of the drug when chewed and then taken…